# Apyx Lowers 2026 Expense Target, Keeps Revenue Outlook at $59 Million to $60 Million

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/50531
Published: 2026-11-07T02:56:22.000Z
Updated: 2026-11-07T02:56:22.000Z
Section: Business

> Third-quarter revenue rose 9% year over year to $14 million, led by a 17% gain in Surgical Aesthetics revenue.

Apyx Medical Corporation (NASDAQ: APYX) held its 2026 revenue forecast at $59 million to $60 million and lowered its operating expense target, narrowing the cost range while preserving its sales outlook.

The company now expects full-year operating expenses of $41 million to $42.5 million, replacing its previous target of less than $45 million. Its revenue forecast includes $54 million to $55 million from Surgical Aesthetics and about $5 million from original-equipment-manufacturer sales. Apyx expects gross margins of 63% to 65%. The revenue outlook compares with $52.8 million in 2025.

For the three months ended Sept. 30, revenue reached $14 million, up 9% year over year. Surgical Aesthetics revenue rose 17% to $13 million, while original-equipment-manufacturer revenue fell 42% to about $1.1 million.

Quarterly operating expenses increased to $9.6 million from $9.1 million. Net loss attributable to stockholders narrowed to $1.8 million from $2 million.